Ratio Therapeutics
Ratio Therapeutics: Innovating targeted radiotherapeutics for cancer treatment.
Founded
2021Ratio Therapeutics: Innovating targeted radiotherapeutics for cancer treatment.
Founded with a mission to revolutionize cancer treatment, Ratio Therapeutics is a pharmaceutical company focused on developing best-in-class targeted radiotherapeutics. Utilizing innovative technologies, the company aims to create advanced radiopharmaceuticals that specifically target cancer cells. Their flagship technology, Trillium™, combines pharmacokinetic modulation with superior chelation methods to develop proprietary small molecule targeting agents. Ratio Therapeutics is committed to advancing from discovery through early clinical phases to bring effective cancer treatments to market.
Ratio Therapeutics has garnered attention for its cutting-edge approach and has attracted notable investors and industry experts. The company’s achievements include significant advancements in targeted radiotherapeutic technologies and successful early-phase clinical trials. Their impact is marked by the potential to significantly improve cancer treatment outcomes, offering more precise and effective options for patients. Through their innovative solutions, Ratio Therapeutics is poised to make a substantial contribution to the field of oncology.
Companies similar to Ratio Therapeutics include Radionetics Oncology, Radimmune Therapeutics, Nucleus RadioPharma and Radiomedix.
Ratio Therapeutics was founded in 2021.
Ratio Therapeutics' headquarters is located in Boston, MA, US.
Ratio Therapeutics' most recent funding round was for $50M (USD) in January 2024.
As of Jan 17, 2024, Ratio Therapeutics has disclosed funding of $90M (USD). Undisclosed round amounts are excluded.
Ratio Therapeutics has 16 employees as of Feb 5, 2024.
Radiomedix
radiomedix.com
